For research use only. Not for therapeutic Use.
Selgantolimod (GS-9688)(Cat.No:I017666) is an investigational oral immune modulator targeting the toll-like receptor 8 (TLR8). It has shown potential in enhancing immune responses by promoting the activation of dendritic cells and macrophages, thereby stimulating both innate and adaptive immunity. Primarily explored for its role in the treatment of chronic hepatitis B (HBV), Selgantolimod aims to activate the immune system to clear HBV-infected cells and reduce viral replication. Its use may extend to other immune-related conditions with ongoing clinical trials.
| Catalog Number | I017666 |
| CAS Number | 2004677-13-6 |
| Molecular Formula | C₁₄H₂₀FN₅O |
| Purity | ≥95% |
| IUPAC Name | (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino]-2-methylhexan-1-ol |
| InChI | 1S/C14H20FN5O/c1-3-4-5-14(2,8-21)20-12-11-10(18-13(16)19-12)6-9(15)7-17-11/h6-7,21H,3-5,8H2,1-2H3,(H3,16,18,19,20)/t14-/m1/s1 |
| InChIKey | HTCJUBZBSJQWBW-CQSZACIVSA-N |
| SMILES | CCCC[C@](C)(CO)NC1=NC(=NC2=C1N=CC(=C2)F)N |
